The promising safety profile and anti-tumor activity demonstrated by the combination of DV and PD-1 inhibitors in this real-world study lay a solid foundation for a phase 2 clinical trial exploring DV in combination with PD-1 inhibitors in patients with MIBC. This evidence concerns the gene PDCD1 and neoplasm.